Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) EPS (Basic) (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed EPS (Basic) for 3 consecutive years, with -$0.71 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, EPS (Basic) fell 12.7% year-over-year to -$0.71, compared with a TTM value of -$3.47 through Dec 2021, down 69.27%, and an annual FY2024 reading of -$1.27, up 32.45% over the prior year.
  • EPS (Basic) was -$0.71 for Q4 2021 at Black Diamond Therapeutics, up from -$0.97 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.41 in Q2 2020 and bottomed at -$5.99 in Q2 2019.
  • Average EPS (Basic) over 3 years is -$1.88, with a median of -$0.9 recorded in 2021.
  • The sharpest move saw EPS (Basic) soared 93.16% in 2020, then plummeted 131.71% in 2021.
  • Year by year, EPS (Basic) stood at -$4.63 in 2019, then skyrocketed by 86.39% to -$0.63 in 2020, then fell by 12.7% to -$0.71 in 2021.
  • Business Quant data shows EPS (Basic) for BDTX at -$0.71 in Q4 2021, -$0.97 in Q3 2021, and -$0.95 in Q2 2021.